About TMD

TMD is dedicated to improving the survival and quality of lives of cancer patients by using biomarker technologies to support the development of targeted therapies. Located in Westmont, IL near Chicago, the company currently supports the development of numerous targeted therapies in oncology such as EGFR, HER2, SRC, MEK, PI3K, HDAC and VEGF inhibitors.

With a wide variety of technologies, expert clinical and research staff, full CAP and CLIA certification and GLP and GCP compliance, TMD is well-positioned to support the emerging needs of targeted therapy development. The laboratory employs a comprehensive set of technologies, such as IHC, FISH, quantitative Real-Time PCR, gene expression microarrays, image analysis and tissue microarrays (TMA), that are necessary for the pre-clinical and clinical development of targeted therapies. TMD’s infrastructure also enables it to develop assays that can be used for screening of patients in clinical trials. TMD currently supports clinical trials for pharmaceutical and biotech companies in over 40 countries and offers over 100 biomarker assays.